19:34 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammation Mouse studies identified a peptide-based inhibitor of the LTBR-TRAF3 interaction that could help treat contact hypersensitivity. The fusion consists of a 28-amino acid, cell-penetrating peptide from the N-terminus of...
14:16 , Nov 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Scleroderma Mouse and cell cultures studies suggest agonizing LTBR in adipose-derived mesenchymal stromal cell (ADSC) grafts could help treat skin fibrosis in scleroderma. ADSC numbers were lower in the dermal white adipose tissue (WAT)...
07:00 , Mar 15, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Viral infection Lymphotoxin-a (LTA); LTB (p33) Mouse studies suggest lymphotoxin could be used to stimulate the innate immune response against neurotropic viruses. In a...
07:00 , Mar 15, 2012 |  BC Innovations  |  Targets & Mechanisms

Antibodies not needed

Italian and American researchers have mouse data showing that the most important function of B cells in fighting some viral infections is not making antibodies but rather stimulating an innate immune response led by macrophages....
07:00 , Aug 29, 2011 |  BioCentury  |  Strategy

R&D reboot

Charged with a mandate to reinvigorate and streamline R&D and ensure investors see value for money spent, Biogen Idec Inc. 's new management has pruned the pipeline and instilled a new culture of intelligent risk...
07:00 , Mar 25, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Lymphotoxin-b (LTb); LTb receptor (LTBR) A study in mice and in patient samples suggests that blocking LTb expression in B cells could help...
07:00 , Mar 25, 2010 |  BC Innovations  |  Cover Story

A B cell burden in prostate cancer

Although castration therapies such as androgen ablation are standard prostate cancer treatments, many patients develop resistance in 12-18 months. 1 Now, researchers from the University of California, San Diego and Scripps Florida have found that...
08:00 , Jan 11, 2010 |  BioCentury  |  Strategy

Evolution of Biogen Idec's Pipeline

Evolution of Biogen Idec's Pipeline...
07:00 , Oct 13, 2008 |  BC Week In Review  |  Clinical News

Baminercept: Phase IIb data

Top-line data from a double-blind, placebo-controlled, international Phase IIb trial (104RA202) in 380 RA patients who had inadequate response to conventional DMARD therapy, showed that all 5 doses of baminercept missed the primary and secondary...
00:36 , Oct 10, 2008 |  BC Extra  |  Clinical News

Biogen Idec dropping baminercept for RA

Biogen Idec (NASDAQ:BIIB) said it will discontinue development of baminercept for rheumatoid arthritis (RA) after top-line data showed the compound missed the primary and all second endpoints in the Phase IIb 104RA202 trial in 380...